Compare Abeona Therapeutics Inc (ABEO) vs Applied Materials, Inc. (AMAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Applied Materials, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Applied Materials, Inc. trades at $573.98 (market cap $440.25B). The key difference: Applied Materials, Inc. is far larger — about 1179.3× Abeona Therapeutics Inc's market cap, and Applied Materials, Inc. pays a 0.38% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AMAT | |
|---|---|---|
Market Cap | $373.32M | $440.25B |
Sector | Health | Technology |
52-Week High | $7.23 | $723.00 |
52-Week Low | $4.17 | $156.25 |
Enterprise Value | $228.22M | $439.28B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Applied Materials (AMAT) trades at $592.79, down 1.78% on the day, amid a broader bullish technical trend. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.86 surpassing the $2.68 estimate. Strong profitability is evident with a net income margin of 29.31% and ROE of 39.69%. Recent news highlights the company's positioning in the AI-driven semiconductor equipment boom, with the CEO calling it 'the greatest time in the history of our industry' (CNBC, 2026-05-28).
The outlook remains positive, supported by robust analyst sentiment (76.92% buy ratings) and a consensus price target of $622.57, offering potential upside. Key risks include high valuation multiples (P/E of 55.77) and dependence on sustained semiconductor capital expenditure cycles. The stock presents an opportunity for growth investors aligned with the AI infrastructure theme, but requires monitoring of execution and market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →
